Ashkenazi Jews

Genetic Health Service Provider, Panacea, Launches to Make Whole Exome Sequencing Accessible to Consumers Without Insurance Barriers

Retrieved on: 
Wednesday, February 28, 2024

PALM BEACH, Fla., Feb. 28, 2024 /PRNewswire/ -- Panacea, the one-stop-shop for genetic health services making potentially life-saving testing accessible for consumers, today announced its nationwide* commercial availability, without needing to visit a doctor or receive approval from insurance.

Key Points: 
  • The problem is that current guidelines for doctors to order genetic tests, and for insurance to approve it, are missing about half of the people with genetic mutations.
  • "I had my exome sequenced with Panacea, even though I was not a candidate for testing based on today's medical guidelines.
  • This further inspired me to make clinical-grade whole exome sequencing more accessible, so everyone can make informed decisions about their future."
  • For more information on Panacea or on whole exome sequencing, please visit seekpanacea.com .

Regula Urges Awareness as Identity Theft Soars to a Record 3205 Data Compromises

Retrieved on: 
Tuesday, January 30, 2024

RESTON, Va., Jan. 30, 2024 /PRNewswire/ -- In a landscape saturated with staggering statistics, the need for innovative solutions to safeguard against the usage of stolen identities becomes more pronounced. The gravity of identity-related crimes is illustrated by the Identity Theft Resource Center's annual report, disclosing a record 3205 data compromises in 2023, marking a seismic 78% increase from the prior year. These breaches facilitated hackers in gaining unauthorized access to the personal information of millions of consumers.

Key Points: 
  • Amidst an alarming surge in identity-related crimes, Regula, a global developer of forensic devices and identity verification solutions, calls for heightened vigilance during Identity Theft Awareness Week.
  • The gravity of identity-related crimes is illustrated by the Identity Theft Resource Center's annual report , disclosing a record 3205 data compromises in 2023, marking a seismic 78% increase from the prior year.
  • Shields Healthcare Group, a Massachusetts-based medical services provider, saw the theft of sensitive patient information and confidential data in a breach that affected approximately 2.3 million people.
  • The breach exposed large volumes of often-sensitive data, including pension information, social security numbers, medical records, and billing data.

How a French rabbi helped build a thriving Jewish community in medieval York – before a shocking massacre

Retrieved on: 
Saturday, December 30, 2023

The event was led by Rabbi Elisheva Salamo, the first rabbi to live in York for over 700 years.

Key Points: 
  • The event was led by Rabbi Elisheva Salamo, the first rabbi to live in York for over 700 years.
  • In the history of England’s Jewish communities, York is forever linked with this period of murderous antisemitism.
  • Historians have long examined how the Christian and Jewish communities co-existed in York both before and, crucially, after 1190.

York’s early Jewish community

  • The first references to a Jewish community in York date back to the 1170s.
  • Property deeds held in York City Archives and Durham Cathedral Archives refer to two very substantial properties, occupied by two prominent Jewish figures, Josce and Benedict.
  • At some point in the 1180s, he wrote to the Jewish community in Joigny, just south-east of Paris, asking for a scholar to be sent to York to teach the community.

A centre of Jewish scholarship and poetry

  • Research suggests York was a centre
    of Jewish scholarship and poetry.
  • Specifically, Yom Tov said that it was acceptable to allow a gentile into a Jewish household on Chabbad (the Sabbath) for the purposes of the lighting a fire.
  • As Rabbi Edward Feld notes, the poem is favoured for its insistence that only God can rescue humanity, through his forgiveness.
  • Historical chroniclers do not agree on whether Yom Tov lived permanently in York, as the city’s rabbi, or whether he was simply a frequent visitor.
  • This strongly suggests Yom Tov was, in fact, established in York.

Jews were absent from York for 600 years

  • The 12th-century English chronicler, William of Newburgh, describes Josce and Benedict’s “stone palaces” as “[attracting] the attention of their Christian neighbours”.
  • In an antisemitic attempt at justification, he implies that their lavishness inspired envy and contributed to the “cause” of the pogrom.
  • Charter evidence suggests around 150 people died – likely, the entirety of the York community.
  • Following the expulsion of the Jews from England, by King Edward I, in 1290, there would be no Jewish presence in York for 600 years.
  • The return of a resident rabbi in York, in 2023, comes amid plans to build a new synagogue.


Louise Hampson works for The University of York. She receives funding from the AHRC and this work on which this articlke is based arose from a government-funded project. John Jenkins does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

‘Getting the Village Back Together’: ChristianaCare’s Plan for Reducing Breast Cancer Disparities in Delaware

Retrieved on: 
Wednesday, November 1, 2023

Wilmington, Delaware, Nov. 01, 2023 (GLOBE NEWSWIRE) -- There’s a tried and proven pathway to reducing racial disparities in cancer in Delaware.

Key Points: 
  • Wilmington, Delaware, Nov. 01, 2023 (GLOBE NEWSWIRE) -- There’s a tried and proven pathway to reducing racial disparities in cancer in Delaware.
  • The commentary — "Reducing Racial Disparities in Breast Cancer: Getting the Village Back Together" — is a call to action for community members, health care providers and other stakeholders to partner together to address disparities in breast cancer.
  • According to the National Cancer Institute, Delaware leads the country in incidences of late-stage breast cancer among women younger than 50.
  • “We are excited at the possibility of bringing the larger village back together again to tackle the disparities in breast cancer.

23andMe Granted New FDA Clearance to Report Additional BRCA Variants

Retrieved on: 
Thursday, August 31, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced the Company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report*. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer. 23andMe received the first FDA authorization for a direct-to-consumer genetic test for cancer risk in 2018 to report 3 variants in the BRCA1 and BRCA2 genes, primarily found in people of Ashkenazi Jewish descent. Many of the 41 BRCA variants added through this clearance are known to have a higher rate of occurrence in populations traditionally underserved by genetic testing, including the African American and Hispanic/Latino communities. This marks the Company’s fourth FDA clearance for genetic cancer risk.

Key Points: 
  • The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer.
  • In addition to the 510(k) clearance, the FDA also granted 23andMe the first-ever Predetermined Change Control Plan (PCCP), which allows the Company to add additional validated BRCA1 and BRCA2 variants and associated cancer risk information to its BRCA1/BRCA2 (Selected Variants) report without additional premarket review.
  • 23andMe also underwent robust analytical validation in order to meet FDA requirements to add variants to the BRCA1/BRCA2 (Selected Variants) report.
  • This clearance is the eighth pre-market authorization granted by the FDA to 23andMe covering its multiplexed Personal Genome Service.

Global Consortium Identifies Novel Parkinson's Genetic Risk Factor in African Populations

Retrieved on: 
Thursday, August 24, 2023

The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.

Key Points: 
  • The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.
  • BLAAC PD is a cross-sectional study collecting a blood or saliva sample and clinical data from Black and African Americans.
  • ASAP launched GP2 in 2019, building on previous funding efforts from MJFF to expand global genetics study in populations traditionally underrepresented in research.
  • Fox Foundation supported the Edmond J. Safra Global Genetics Consortia to generate and share genetics data in varied international populations.

Global Consortium Identifies Novel Parkinson's Genetic Risk Factor in African Populations

Retrieved on: 
Thursday, August 24, 2023

The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.

Key Points: 
  • The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry.
  • BLAAC PD is a cross-sectional study collecting a blood or saliva sample and clinical data from Black and African Americans.
  • ASAP launched GP2 in 2019, building on previous funding efforts from MJFF to expand global genetics study in populations traditionally underrepresented in research.
  • Fox Foundation supported the Edmond J. Safra Global Genetics Consortia to generate and share genetics data in varied international populations.

Wistar Scientists Discover Innate Tumor Suppression Mechanism

Retrieved on: 
Thursday, May 4, 2023

Now, in a recent study published in Cancer Discovery , a journal of the American Association for Cancer Research, researchers at The Wistar Institute have uncovered a key mechanism as to how p53 suppresses tumors.

Key Points: 
  • Now, in a recent study published in Cancer Discovery , a journal of the American Association for Cancer Research, researchers at The Wistar Institute have uncovered a key mechanism as to how p53 suppresses tumors.
  • Publication information: An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression, Cancer Discovery, 2023.
  • Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology.
  • Consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology, Wistar scientists’ early-stage discoveries shorten the path from bench to bedside.

23andMe Reports FY2023 Third Quarter Financial Results

Retrieved on: 
Wednesday, February 8, 2023

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3) of its fiscal year 2023 (FY2023), which ended December 31, 2022. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health risk reports, and in particular the only company the FDA has authorized to provide, without physician involvement, genetic cancer risk reports and medication insights on how individuals may process certain commonly prescribed medications based on their genetics. The Company has also created the world’s largest crowdsourced platform for genetic research, which it is using to pursue drug discovery programs rooted in human genetics across a spectrum of disease areas.

Key Points: 
  • These reports are developed by 23andMe scientists using data and insights gathered from thousands of customers who have consented to participate in our research.
  • “Our fiscal third quarter results reflect solid revenue growth in our consumer business, despite the macro-economic headwinds, and give us confidence to raise our full year financial guidance,” said Joe Selsavage, Interim Chief Financial and Accounting Officer of 23andMe.
  • 23andMe is raising its full year guidance following Q3 FY2023 results.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time on Wednesday, February 8, 2023 to discuss the financial results for Q3 FY2023 and report on business progress.

Recently Published Study Using Ikonopedia Analytics Demonstrates Age as a Significant Risk Factor for Breast Arterial Calcifications (BAC)

Retrieved on: 
Monday, November 28, 2022

CHICAGO, Nov. 28, 2022 /PRNewswire/ -- Ikonopedia, a leading developer of an innovative cloud-based structured breast reporting and MQSA (Mammography Quality Standards Act) management system, announced a study, published this month in the Annals of Epidemiology using the company's powerful analytical solutions, demonstrate age can be a significant risk factor for breast arterial calcifications (BAC). The retrospective study involved the review and analysis of more than 17,000 digital mammography patient records. The company is showcasing the analytical tools used in the study at the annual Radiological Society of North America (RSNA) conference being held November 27-30, 2022 in Chicago.

Key Points: 
  • CHICAGO, Nov. 28, 2022 /PRNewswire/ -- Ikonopedia, a leading developer of an innovative cloud-based structured breast reporting and MQSA (Mammography Quality Standards Act) management system, announced a study, published this month in the Annals of Epidemiology using the company's powerful analytical solutions, demonstrate age can be a significant risk factor for breast arterial calcifications (BAC).
  • Using comprehensive analytics, such as those enabled by Ikonopedia, the assessment of BAC would add minimal exam time
    "This groundbreaking study indicates the risk of BAC doubles for every 10 years of age," said Emily Crane, president and CEO of Ikonopedia.
  • These analytics help identify the types of cancer, breast tissue density, compliance and other high risk indicators by age group to help assist in managing patient populations.
  • These analytics help identify the types of cancer, breast tissue density, compliance and other high risk indicators by age group to help assist in managing patient populations.